HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir

AIDS Research and Human Retroviruses

Volumn 26, Issue 12, 2010, Pages 1323-1326

  Varghese, Vici ^a   Liu, Tommy F ^a   Rhee, Soo Yon ^a   Libiran, Paolo ^a   Trevino, Christina ^a   Fessel, W Jeffrey ^b   Shafer, Robert W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; RALTEGRAVIR; RNA;

ANTIVIRAL RESISTANCE; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG TREATMENT FAILURE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; TREND STUDY; VIRUS MUTATION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; GENETIC VARIATION; HIV INFECTIONS; HIV INTEGRASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PYRROLIDINONES; SEQUENCE ANALYSIS, DNA;

EID: 78650263450     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0123     Document Type: Article

References (15)

1. Goldgur Y, Craigie R, Cohen GH, et al.: Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc Natl Acad Sci USA 1999;96:13040-13043.
2. Chen JC, Krucinski J, Miercke LJ, et al.: Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding. Proc Natl Acad Sci USA 2000;97:8233-8238.
3. Wang JY, Ling H, Yang W, and Craigie R: Structure of a two-domain fragment of HIV-1 integrase: Implications for domain organization in the intact protein. EMBO J 2001;20: 7333-7343.
4. Alian A, Griner SL, Chiang V, et al.: Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc Natl Acad Sci USA 2009; 106:8192-8197.
5. Low A, Prada N, Topper M, et al.: Natural polymorphisms of human immunodeficiency virus type 1 integrase and in-herent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009;53:4275-4282.
6. Myers RE and Pillay D: Analysis of natural sequence vari-ation and covariation in human immunodeficiency virus type 1 integrase. J Virol 2008;82:9228-9235.
7. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, and Perno CF: Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009; 11:17-29.
8. Bushman FD and Miller MD: Tethering human immunode-ficiency virus type 1 preintegration complexes to target DNA promotes integration at nearby sites. J Virol1997;71:458-464.
9. De Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-3800.
10. Rhee SY, Liu TF, Kiuchi M, et al.: Natural variation of HIV-1 group M integrase: Implications for a new class of anti-retroviral inhibitors. Retrovirology 2008;5:74.
11. Garrido C, Geretti AM, Zahonero N, et al.: Integrase variability and susceptibility to HIV integrase inhibitors: Impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010;65:320-326.
12. Eshleman SH, Hudelson SE, Smith P, et al.: Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses 2009;25:343-345.
13. Van Hal SJ, Herring B, Deris Z, Wang B, Saksena NK, and Dwyer DE: HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology 2009;6:12.
14. Brennan CA, Stramer SL, Holzmayer V, et al.: Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion 2009;49:125-133.
15. Sichtig N, Sierra S, Kaiser R, et al.: Evolution of raltegravir re-sistance during therapy. J Antimicrob Chemother 2009;64:25-32.